Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Overview of attention for article published in Frontiers in Public Health, September 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 7,582 followers.

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China #lymphoma #lymsm https://t.co/JA5ILJkXR9

10 Oct 2022

Reply Repost Favourite

10 Oct 2022

Reply Repost Favourite

New Research: Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China: Objective Six anaplastic… https://t.co/dMfgwS1tyw #Public

21 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.